IO Biotech (NASDAQ:IOBT) specializes in pioneering new pathways for immunotherapy to combat cancer. The focus of the company centers on the development of disruptive immune-modulating anti-cancer therapies designed to empower the immune system to defeat cancer. An essential part of IO Biotech's portfolio involves its proprietary T-win® technology platform, aiming at identifying and developing novel immune-modulating compounds. Current projects are geared towards advancing these innovative treatments through clinical trials, targeting a range of cancer types with the ultimate objective of bringing breakthrough solutions to patients in need. IO Biotech's mission revolves around transforming cancer treatment by unlocking the power of the immune system, demonstrating a commitment to cutting-edge research and the development of therapies that offer hope for improved outcomes in cancer care.